Log in | Register

Increased perioperative mortality following aprotinin withdrawal: a real-world analysis of blood management strategies in adult cardiac surgery

Graham J. Walkden| Veerle Verheyden| Rosalind Goudie| Gavin J. Murphy
Original
Volume 39, Issue 10 / October , 2013

Pages 1808 - 1817

Abstract

Purpose

To evaluate the effect of aprotinin withdrawal in 2008 on patient outcomes, to assess the likely risks and benefits of its re-introduction, and to consider the relevance of existing evidence from clinical trials to ‘real-world’ practice.

Methods

We performed a nested case–control study of two cohorts undergoing adult cardiac surgery in a single tertiary centre. The first group underwent surgery between 1 January 2005 and 30 July 2007 (n = 3,578), prior to aprotinin withdrawal; the second group underwent surgery between 1 January 2009 and 31 December 2010 (n = 3,030), after aprotinin withdrawal. Propensity matching was used to select patients matched for 24 covariates in both groups (n = 3,508). We also estimated the effect of aprotinin withdrawal on a subgroup of high-risk patients (n = 1,002). Results were expressed as adjusted odds ratios (OR) and 95 % confidence intervals (CI) for categorical data and hazard ratios (HR) for time-to-event data.

Results

In propensity-matched cohorts, the withdrawal of aprotinin from clinical use was associated with more bleeding, higher rates of emergency re-sternotomy, OR 2.10 (1.04–4.25), and acute kidney injury (AKI), OR 1.86 (1.53–2.25). In high-risk patients, the increases in bleeding and AKI following aprotinin withdrawal were of a greater magnitude. Aprotinin withdrawal was also associated with a significant increase in 30-day mortality, HR 2.51 (1.00–6.29), in the high-risk group. The results were not altered by sensitivity analyses that adjusted for potential selection bias, time series bias and unmeasured confounders.

Conclusions

Aprotinin withdrawal was associated with increased complication rates and patient deaths following cardiac surgery. These real-world findings are at odds with those of randomised trials and cohort studies that have considered the clinical role of aprotinin.

Keywords

References

  1. Karkouti K, Wijeysundera DN, Yau TM, Beattie WS, Abdelnaem E, McCluskey SA, Ghannam M, Yeo E, Djaiani G, Karski J (2004) The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 44:1453–1462
    • View reference on PubMed
    • View reference on publisher's website
  2. Koch CG, Li L, Duncan AI, Mihaljevic T, Cosgrove DM, Loop FD, Starr NJ, Blackstone EH (2006) Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med 34:1608–1616
    • View reference on PubMed
    • View reference on publisher's website
  3. Unsworth-White MJ, Herriot A, Valencia O, Poloniecki J, Smith EE, Murday AJ, Parker DJ, Treasure T (1995) Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 59:664–667
    • View reference on PubMed
    • View reference on publisher's website
  4. UK Transfusion audit. Bridgewater B, Keogh B Demonstrating Quality: The Society of Cardiothoracic Surgeons of Great Britain and Ireland National Sixth Adult Cardiac Surgical Database Report 2008. Dendrite Clinical Systems, Oxfordshire
  5. Bridgewater B, Keogh B Demonstrating Quality: The Society of Cardiothoracic Surgeons of Great Britain and Ireland National Sixth Adult Cardiac Surgical Database Report 2008. Dendrite Clinical Systems, Oxforshire
  6. Ferraris VA, Brown JR, Despotis GJ, Hammon JW, Reece TB, Saha SP, Song HK, Clough ER, Shore-Lesserson LJ, Goodnough LT, Mazer CD, Shander A, Stafford-Smith M, Waters J, Baker RA, Dickinson TA, Fitzgerald DJ, Likosky DS, Shann KG (2011) 2011 update to the society of thoracic surgeons and the society of cardiovascular anesthesiologists blood conservation clinical practice guidelines. Ann Thorac Surg 91:944–982
    • View reference on PubMed
    • View reference on publisher's website
  7. Ranucci M, Aronson S, Dietrich W, Dyke CM, Hofmann A, Karkouti K, Levi M, Murphy GJ, Sellke F, Shore-Lesserson L, von Heymann C (2011) Patient blood management during cardiac surgery: do we have enough evidence for clinical practice? J Thorac Cardiovasc Surg 142:249.e1–249.e32
  8. Henry DA, Carless PA, Moxey AJ, O’Connell D, Stokes BJ, Fergusson DA, Ker K (2011) Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 16:CD001886
  9. Mangano DT, Tudor IC, Dietzel C, Multicenter Study of Perioperative Ischemia Research Group, Ischemia Research and Education Foundation (2006) The risk associated with aprotinin in cardiac surgery. N Engl J Med 354:353–365
    • View reference on PubMed
    • View reference on publisher's website
  10. Shaw AD, Stafford-Smith M, White WD, Phillips-Bute B, Swaminathan M, Milano C, Welsby IJ, Aronson S, Mathew JP, Peterson ED, Newman MF (2008) The effect of aprotinin on outcome after coronary-artery bypass grafting. N Engl J Med 358:784–793
    • View reference on PubMed
    • View reference on publisher's website
  11. Schneeweiss S, Seeger JD, Landon J, Walker AM (2008) Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358:771–783
    • View reference on PubMed
    • View reference on publisher's website
  12. Fergusson DA, Hébert PC, Mazer CD, Fremes S, MacAdams C, Murkin JM et al (2008) A comparison of aprotinin and lysine analogues in high-risk cardiac surgery. N Engl J Med 358:2319–2331
    • View reference on PubMed
    • View reference on publisher's website
  13. Beattie WS, Karkouti K (2011) The post-BART anti-fibrinolytic dilemma. J Cardiothorac Vasc Anesth 25:3–5
    • View reference on PubMed
    • View reference on publisher's website
  14. Gayat E, Pirracchio R, Resche-Rigon M, Mebazaa A, Mary JY, Porcher R (2010) Propensity scores in intensive care and anaesthesiology literature: a systematic review. Intensive Care Med. doi:10.1007/s00134-010-1991-5
  15. Rosenbaum PR, Rubin DB (1983) The central role of the propensity score in observational studies for causal effects. Biometrika 70:41–55
    • View reference on publisher's website
  16. Rosenbaum PR, Rubin DB (1985) Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 39:33–38
  17. Ichino A, Mealli F, Mannicini T (2008) From temporary help jobs to permanent employment: what can we learn from matching estimators and their sensitivity? J Appl Econom 23:203–227
    • View reference on publisher's website
  18. Hutton B, Joseph L, Fergusson D, Mazer CD, Shapiro S, Tinmouth A (2012) Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observational studies. BMJ 345:e5798
    • View reference on PubMed
    • View reference on publisher's website
  19. Howell N, Senanayake E, Freemantle N, Pagano D (1013) Putting the record straight on aprotinin as safe and effective: results from a mixed treatment meta-analysis of trials of aprotinin. J Thorac Cardiovasc Surg 145:234–240
    • View reference on publisher's website
  20. Brown JR, Birkmeyer NJ, O’Connor GT (2007) Meta-analysis comparing the effectiveness and adverse outcomes of antifibrinolytic agents in cardiac surgery. Circulation 115:2801–2813
    • View reference on PubMed
    • View reference on publisher's website
  21. Gagne JJ, Griesdale DE, Schneeweiss S (2009) Aprotinin and the risk of death and renal dysfunction in patients undergoing cardiac surgery: a meta-analysis of epidemiologic studies. Pharmacoepidemiol Drug Saf 18:259–268
    • View reference on PubMed
    • View reference on publisher's website
  22. Meybohm P, Herrmann E, Nierhoff J, Zacharowski K (2013) Aprotinin may increase mortality in low and intermediate risk but not in high risk cardiac surgical patients compared to tranexamic acid and epsilon-aminocaproic acid—a meta-analysis of randomised and observational trials over 30,000 patients. PLoS ONE. doi:10.1371/journal.pone.0058009
  23. Pagano D, Howell NJ, Freemantle N, Cunningham D, Bonser RS, Graham TR, Mascaro J, Rooney SJ, Wilson IC, Cramb R, Keogh BE (2008) Bleeding in cardiac surgery: the use of aprotinin does not affect survival. J Thorac Cardiovasc Surg 135:495–502
    • View reference on PubMed
    • View reference on publisher's website
  24. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Hu S (2010) Effects of aprotinin on short-term and long-term outcomes after coronary artery bypass grafting surgery. Ann Thorac Surg 89:1489–1495
    • View reference on PubMed
    • View reference on publisher's website
  25. Dietrich W, Busley R, Boulesteix AL (2008) Effects of aprotinin dosage on renal function: an analysis of 8,548 cardiac surgical patients treated with different dosages of aprotinin. Anesthesiology 108:189–198
    • View reference on PubMed
    • View reference on publisher's website
  26. Karkouti K, Wijeysundera DN, Yau TM, McCluskey SA, Tait G, Beattie WS (2010) The risk-benefit profile of aprotinin versus tranexamic acid in cardiac surgery. Anesth Analg 110:21–29
    • View reference on PubMed
    • View reference on publisher's website
  27. Ngaage DL, Cale AR, Cowen ME, Griffin S, Guvendik L (2008) Aprotinin in primary cardiac surgery: operative outcome of propensity score-matched study. Ann Thorac Surg 86:1195–1202
    • View reference on PubMed
    • View reference on publisher's website
  28. Furnary AP, Wu Y, Hiratzka LF, Grunkemeier GL, Page US 3rd (2007) Aprotinin does not increase the risk of renal failure in cardiac surgery patients. Circulation 116:127–133
    • View reference on publisher's website
  29. Bryan AJ, Cohen AM, Davies A. Bristol Heart Institute Cardiac Services Adult Cardiac Surgery Activity Report 2009-10. Available via http://www.uhbristol.nhs.uk/media/1467094/acsar09-10_ad_2_feb_2012.pdf. Accessed 1st Jul 2013
  30. Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C (2010) Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis. Crit Care 14:R148
    • View reference on PubMed
    • View reference on publisher's website
  31. Strouch ZY, Drum ML, Chaney MA (2009) Aprotinin use during cardiac surgery: recent alterations and effects on blood product utilization. J Clin Anesth 21:502–507
    • View reference on PubMed
    • View reference on publisher's website
  32. Wang X, Zheng Z, Ao H, Zhang S, Wang Y, Zhang H, Li L, Hu S (2009) A comparison before and after aprotinin was suspended in cardiac surgery: different results in the real world from a single cardiac center in China. J Thorac Cardiovasc Surg 138:897–903
    • View reference on PubMed
    • View reference on publisher's website
  33. Sniecinski RM, Chen EP, Makadia SS, Kikura M, Bolliger D, Tanaka KA (2010) Changing from aprotinin to tranexamic acid results in increased use of blood products and recombinant factor VIIa for aortic surgery requiring hypothermic arrest. J Cardiothorac Vasc Anesth 24:959–963
    • View reference on PubMed
    • View reference on publisher's website
  34. Martin K, Wiesner G, Breuer T, Lange R, Tassani P (2008) The risks of aprotinin and tranexamic acid in cardiac surgery: a one-year follow-up of 1188 consecutive patients. Anesth Analg 107:1783–1790
    • View reference on PubMed
    • View reference on publisher's website

Sign In

Connect with ICM

Top 5 Articles Editors Picks Supplement